Report of Foreign Issuer (6-k)
06 September 2018 - 6:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2018
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name into
English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):
¨
On September 5, 2018, Cellect Biotechnology
Ltd. (the “Company”) determined to withdraw the sole proposal to elect an external director at the Company’s
Extraordinary Meeting of Shareholders, which was scheduled to be held on September 6, 2018, due to a conflict of interest that
disqualified the candidate from serving as an external director. Accordingly, the Extraordinary Meeting of Shareholders has been
cancelled. The Company intends to propose a new candidate for election as an external director and to convene a shareholders’
meeting to approve such candidate at the earliest opportunity.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Cellect Biotechnology Ltd.
|
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Name: Eyal Leibovitz
|
Date: September 5, 2018
|
|
Title: Chief Financial Officer
|
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Apr 2024 to May 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Cellect Biotechnology Ltd (NASDAQ): 0 recent articles
More Cellect Biotechnology Ltd. News Articles